SCHEMBL311580

SCHEMBL311580

O=c1cc(-c2cccc(O)c2)oc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 5/20 1.00
PARP1 P09874 4/20 1.00
TNKS2 Q9H2K2 4/20 1.00
CYP3A4 P08684 5/20 0.78
HPGD P15428 4/20 0.78
SMN1; SMN2 Q16637 4/20 0.78
MAPT P10636 4/20 0.78
ALDH1A1 P00352 3/20 0.78
TP53 P04637 2/20 0.78
MEN1 O00255 1/20 0.78
CYP2C9 P11712 1/20 0.78
KMT2A Q03164 1/20 0.78
GLA P06280 1/20 0.78
NPC1 O15118 3/20 0.72
RAB9A P51151 3/20 0.72
KDM4E B2RXH2 2/20 0.72
BCHE P06276 1/20 0.72
POLB P06746 1/20 0.72
ACHE P22303 1/20 0.72
TDP1 Q9NUW8 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29677954 1.00 TNKS (1.00) TNKSPARP1TNKS2CYP3A4HPGD
SCHEMBL29384142 1.00 TNKS (1.00) TNKSPARP1TNKS2CYP3A4HPGD
Flavone SCHEMBL27534477 0.89 TNKS (0.85) TNKSPARP1TNKS2CYP3A4HPGD
SCHEMBL4277649 0.88 MAPT (1.00) TNKSPARP1TNKS2CYP3A4HPGD
SCHEMBL3135989 0.88 CYP3A4 (1.00) TNKSPARP1TNKS2CYP3A4HPGD
SCHEMBL31675776 0.88 CYP3A4 (1.00) TNKSPARP1TNKS2CYP3A4HPGD
SCHEMBL1483977 0.87 TNKS (0.77) TNKSPARP1TNKS2CYP3A4HPGD
SCHEMBL29773081 0.84 TNKS (1.00) TNKSPARP1TNKS2CYP3A4HPGD
SCHEMBL127446 0.84 TNKS (1.00) TNKSPARP1TNKS2CYP3A4HPGD
Flavone SCHEMBL15676601 0.83 TNKS (1.00) TNKSPARP1TNKS2CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230119060-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE MEDIENCE CO., LTD. (KR) 2023-04-20 US claimed
US-20220249431-A1 ANTIMYCOTIC Karl-Franzens-Universität Graz (AT) 2022-08-11 US claimed
EP-4003522-A1 ANTIMYCOTIC Karl-Franzens-Universität Graz (AT) 2022-06-01 EP claimed
WO-2021013931-A1 ANTIMYCOTIC Karl-Franzens-Universität Graz (AT) 2021-01-28 WO claimed
EP-3769815-A1 ANTIMYCOTIC Karl-Franzens-Universität Graz (AT) 2021-01-27 EP claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
US-20040086983-A1 Method for producing a heterocyclic compound and an aromatic carboxylic acid having one or more hydroxyl groups, and modified aromatic ring dioxygenase MARINE BIOTHECHNOLOGY INSTITUTE., LTD. (JP) 2004-05-06 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO claimed
US-20250263774-A1 DISCOVERING NEW XENOBIOTIC SUBSTRATES OF AN UDP-GLYCOSYLTRANSFERASE WITH A HIGH-THROUGHPUT METHOD UNIV NORTH TEXAS (US) 2025-08-21 US disclosed
CN-118001403-A Method for preparing phosphoric acid nano-drug based on competitive coordination and multifunctional nano-drug 吉林大学 2024-05-10 CN disclosed
US-11786503-B2 Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity AURANSA INC. (US) 2023-10-17 US disclosed
CN-114014905-B Glycyrrhetinic acid derivative targeting PPARgamma as well as preparation method and application thereof 浙江科技学院 2023-07-21 CN disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-09-12 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones CBR3, FOS, CBR1 TNKS 4063/4885PARP1 3627/4885TNKS2 4036/4885
US-20220249431-A1 ANTIMYCOTIC ETF1, FOXM1, RIF1 TNKS 4403/4885PARP1 3190/4885TNKS2 4431/4885
US-11786503-B2 Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity RDX, TNNT2, CHLSN TNKS 2925/4885PARP1 953/4885TNKS2 2746/4885
US-20230119060-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE SLC5A2, SLC5A1, SLC5A6 TNKS 4575/4885PARP1 4024/4885TNKS2 4500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.